Breaking News Instant updates and real-time market news.

NFLX

Netflix

$115.21

0.18 (0.16%)

, AGN

Allergan

$192.85

1.07 (0.56%)

10:13
11/21/16
11/21
10:13
11/21/16
10:13

On The Fly: Top five analyst initiations

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Netflix (NFLX) initiated with a Buy at Brean Capital. 2. Allergan (AGN) initiated with a Market Perform at William Blair. 3. Myovant Sciences (MYOV) was initiated with an Overweight at Barclays, an Outperform at JMP Securities, an Outperform at Baird, a Buy at Citi, and an Outperform at Cowen. 4. RA Pharmaceuticals (RARX) was initiated with a Buy at Jefferies, a Buy at SunTrust, and an Outperform at Credit Suisse. 5. ZTO Express (ZTO) was initiated with a Buy ratings at Citi and Goldman and an Overweight at Morgan Stanley. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

NFLX

Netflix

$115.21

0.18 (0.16%)

AGN

Allergan

$192.85

1.07 (0.56%)

MYOV

Myovant Sciences

$10.82

-0.43 (-3.82%)

RARX

RA Pharmaceuticals

$13.29

-0.12 (-0.89%)

ZTO

ZTO Express

$16.57

0.27 (1.66%)

  • 28

    Nov

  • 29

    Nov

  • 29

    Nov

  • 05

    Dec

NFLX Netflix
$115.21

0.18 (0.16%)

11/18/16
MACQ
11/18/16
NO CHANGE
MACQ
Netflix mentioned positively at M Science
11/18/16
WBLR
11/18/16
NO CHANGE
WBLR
Outperform
William Blair calls Netflix net-neutrality fears overblown
Shares of Netflix are down about 8% since President-elect Donald Trump won the election, in part due to growing concerns about potential changes to net-neutrality, William Blair analyst Ralph Schackart tells investors in a research note. Netflix already has paying arrangements in place with the major Internet Service Providers in the United States, and any potential reversal of net-neutrality rules by the Federal Communications Commission would likely not supersede agreements that are already established, Schackart contends. As such, the analyst believes any changes to the rule would likely be a nonevent for Netflix. He remains a long-term believer in Netflix's original content strategy, the "inevitable" shift to over-the-stop streaming, and the company's ability to grow revenue faster than content costs. Schackart's "base case" valuation methodology points to a mid-$140s stock price and his "bull case" has a stock price of $185. Netflix closed yesterday at $115.03.
11/21/16
BMUR
11/21/16
INITIATION
Target $145
BMUR
Buy
Netflix initiated with a Buy at Brean Capital
Brean Capital analyst Alan Gould started Netflix with a Buy rating and $145 price target. The company has created an "unstoppable lead" in the internet TV business and is positioned to dominate the business long term, Gould tells investors in a research note. He believes Netflix over the next 15 years can attract 300M global subscribers and generate over $25 of earnings per share. The stock closed Friday up 18c to $115.21.
11/18/16
RBCM
11/18/16
NO CHANGE
RBCM
Internet stock weakness creates buying opportunity, says RBC Capital
EBC Capital analyst Mark Mahaney says that the 5%-10% decline in Internet stocks since the election has created more attractive long-term opportunities. The analyst does not expect the Trump Administration's policies to have a major impact on the fundamentals of the Internet sector. His favorite large-cap names in the sector are, in order, Netflix (NFLX), Facebook (FB), and Priceline (PCLN). His favorite small-cap names are, in order, Yelp (YELP), Criteo (CRTO), and GoDaddy (GDDY).
AGN Allergan
$192.85

1.07 (0.56%)

11/03/16
JPMS
11/03/16
NO CHANGE
JPMS
JPMorgan calls Lilly, Bristol-Myers, Allergan favorite pharma majors
Following a "challenging" Q3 earnings season for the major pharmaceuticals companies, JPMorgan analyst Chris Schott said pricing continues to be a major overhang on the space. However, he believes these and other challenges are "increasingly well reflected" in both earnings and sector multiples and recommends companies early in new product launch cycles. Coming out of the earnings season, Schott named Eli Lilly (LLY), Bristol-Myers (BMY) and Allergan (AGN) as his favorite names in the large-cap pharma space.
11/04/16
UBSW
11/04/16
NO CHANGE
Target $240
UBSW
Buy
Allergan price target lowered to $240 from $300 at UBS
UBS analyst Marc Goodman lowered his price target on Allergan to $240 from $300 following disappointing Q3 results and a lowering of his estimates. However, Goodman reiterated his Buy rating on Allergan shares, on the belief it is still a good growth story, has an efficient tax structure and robust pipeline, and has the potential to put up double digit earnings growth for the rest of the decade.
11/03/16
LEER
11/03/16
NO CHANGE
Target $266
LEER
Outperform
Allergan price target lowered to $266 from $294 at Leerink
Leerink analyst Jason Gerberry lowered his price target for Allergan to $266 from $294 after the company reported quarterly results modestly missing revenue and EPS targets, with a slowdown in revenue for some of the company's established products leading to a 2016 guidance rebasing. However, Gerberry reiterates an Outperform rating on the shares as he came away from the quarter update encouraged by robust Q3 sales growth from Allergan's more differentiated/cash pay growth drivers.
11/21/16
WBLR
11/21/16
INITIATION
Target $209
WBLR
Market Perform
Allergan initiated with a Market Perform at William Blair
William Blair analyst Tim Lugo started Allergan with a Market Perform rating and $209 price target. The analyst views the company as high quality but sees headwinds in 2017 and 2018. Renewed competition for Botox could weigh on out-year estimates while a Namenda generic could come sooner than expected, Lugo tells investors in a research note.
MYOV Myovant Sciences
$10.82

-0.43 (-3.82%)

11/21/16
COWN
11/21/16
INITIATION
Target $11
COWN
Outperform
Myovant Sciences initiated with an Outperform at Cowen
Cowen analyst Phil Nadeau initiated Myovant Sciences with an Outperform rating and $11 price target as he believes its Relugolix drug potential is undervalued. He noted it reported a strong proof of concept and should enter pivotal programs in 1H 2017, while projecting peak sales of more than $2B.
11/21/16
JMPS
11/21/16
INITIATION
Target $23
JMPS
Outperform
Myovant Sciences initiated with an Outperform at JMP Securities
JMP Securities analyst Jason Butler initiated Myovant Sciences with an Outperform and a $23 price target. The analyst said lead asset, relugolix, is a potent oral GnRH antagonist entering Phase 3 development in women with uterine fibroids and endometriosis, and in men with advanced prostate cancer. He views this as a substantially de-risked asset with established mechanistic rationale and compelling Phase 2 results in Japan with block buster sales opportunities.
11/21/16
BARD
11/21/16
INITIATION
Target $20
BARD
Outperform
Myovant Sciences initiated with an Outperform at Baird
Baird analyst Brian Skorney initiated Myovant Sciences with an Outperform and a $20 price target.
11/21/16
SBSH
11/21/16
INITIATION
Target $17
SBSH
Buy
Myovant Sciences initiated with a Buy at Citi
Citi analyst Robyn Karnauskas started Myovant Sciences (MYOV) with a Buy rating and $17 price target. The analyst sees upside if the company meets enrollment timelines through 2017. Myovant's Relagolix is validated by Neurocrine's (NBIX) Elagolix, but may have greater convenience and efficacy, Karnauskas contends.
RARX RA Pharmaceuticals
$13.29

-0.12 (-0.89%)

11/21/16
BMOC
11/21/16
INITIATION
Target $26
BMOC
Outperform
RA Pharmaceuticals initiated with an Outperform at BMO Capital
BMO Capital analyst Ian Somaiya started RA Pharmaceuticals with an Outperform rating and $26 price target.
11/21/16
RHCO
11/21/16
INITIATION
Target $32
RHCO
Buy
RA Pharmaceuticals initiated with a Buy at SunTrust
SunTrust analyst Yatin Suneja started RA Pharmaceuticals with a Buy rating and $32 price target.
11/21/16
JEFF
11/21/16
INITIATION
Target $25
JEFF
Buy
RA Pharmaceuticals initiated with a Buy at Jefferies
Jefferies analyst Eun Yang started RA Pharmaceuticals with a Buy rating and $25 price target. The analyst sees greater than 100% potential upside should the Phase II data for RA101495 in paroxysmal nocturnal hemoglobinuria patients be positive in the second half of 2017.
11/21/16
FBCO
11/21/16
INITIATION
Target $19
FBCO
Outperform
RA Pharmaceuticals initiated with an Outperform at Credit Suisse
Credit Suisse analyst Kennen MacKay initiated RA Pharmaceuticals with an Outperform and a $19 price target. The analyst said RA101495 as an attractive drug candidate for patients with paroxysmal nocturnal hemoglobinuria with potential to capture greater than30% market share in patients with unmet need despite Soliris treatment and sees potential peak global sales of $837M.
ZTO ZTO Express
$16.57

0.27 (1.66%)

11/21/16
GSCO
11/21/16
INITIATION
Target $19
GSCO
Buy
ZTO Express initiated with a Buy at Goldman
Goldman Sachs analyst Ronald Keung started ZTO Express with a Buy rating and $19 price target. The company is a leading e-commerce express courier in China with cost leadership, Keung tells investors in a research note.
11/21/16
MSCO
11/21/16
INITIATION
MSCO
Overweight
ZTO Express initiated with an Overweight at Morgan Stanley
Morgan Stanley analyst Edward Xu initiated ZTO Express with an Overweight and a $20 price target.
11/21/16
SBSH
11/21/16
INITIATION
Target $19.72
SBSH
Buy
ZTO Express initiated with a Buy at Citi
Citi analyst Vivian Tao started ZTO Express with a Buy rating and $19.72 price target. The analyst expects ZTO's growth momentum to continue as express volumes in China rise at a 30.5% annual rate over 2015-2020.

TODAY'S FREE FLY STORIES

CME

CME Group

$154.28

2.07 (1.36%)

, GS

Goldman Sachs

$256.12

5.15 (2.05%)

04:55
01/20/18
01/20
04:55
01/20/18
04:55
Conference/Events
American Bar Association to hold annual meeting »

Derivatives & Futures…

CME

CME Group

$154.28

2.07 (1.36%)

GS

Goldman Sachs

$256.12

5.15 (2.05%)

BP

BP

$42.40

-0.5 (-1.17%)

C

Citi

$78.30

0.91 (1.18%)

BAC

Bank of America

$31.72

0.24 (0.76%)

CS

Credit Suisse

$19.06

0.13 (0.69%)

CRL

Charles River

$107.89

1.22 (1.14%)

MS

Morgan Stanley

$57.46

1.62 (2.90%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jan

  • 24

    Jan

  • 31

    Jan

  • 01

    Feb

  • 15

    Feb

AMGN

Amgen

$189.28

1.69 (0.90%)

, BAYRY

Bayer

$32.05

0.235 (0.74%)

04:55
01/20/18
01/20
04:55
01/20/18
04:55
Conference/Events
American Society of Clinical Oncology to hold a symposium »

2018 ASCO…

AMGN

Amgen

$189.28

1.69 (0.90%)

BAYRY

Bayer

$32.05

0.235 (0.74%)

BLRX

BioLineRx

$1.09

-0.02 (-1.80%)

BMY

Bristol-Myers

$62.28

0.45 (0.73%)

CELG

Celgene

$102.65

0.93 (0.91%)

DNA

Bought by RHHBY

ESALY

Eisai

$56.88

0.115 (0.20%)

EXEL

Exelixis

$28.00

0.14 (0.50%)

HALO

Halozyme

$17.98

0.13 (0.73%)

INCY

Incyte

$93.16

1.24 (1.35%)

IPSEY

Ipsen

$34.65

0.75 (2.21%)

LXRX

Lexicon

$10.44

0.2 (1.95%)

MGNX

MacroGenics

$19.19

0.3 (1.59%)

MRK

Merck

$61.28

0.15 (0.25%)

NVS

Novartis

$86.94

0.53 (0.61%)

SNY

Sanofi

$44.60

0.09 (0.20%)

ONCY

Oncolytics

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 25

    Jan

  • 25

    Jan

  • 02

    Feb

  • 03

    Feb

  • 05

    Feb

  • 08

    Feb

  • 15

    Feb

  • 16

    Feb

  • 02

    Mar

  • 05

    Mar

  • 08

    Mar

  • 25

    Mar

  • 03

    Apr

  • 23

    Apr

  • 30

    Apr

  • 02

    May

  • 17

    May

  • 28

    May

  • 23

    Oct

WLFC

Willis Lease

$26.66

0.05 (0.19%)

18:59
01/19/18
01/19
18:59
01/19/18
18:59
Hot Stocks
Willis Lease announces $1,000 bonus for employees »

Willis Lease announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DPS

Dr Pepper Snapple

$96.35

1.03 (1.08%)

18:13
01/19/18
01/19
18:13
01/19/18
18:13
Hot Stocks
Dr Pepper to become official sponsor of esports team TSM »

Dr Pepper announced it is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RCII

Rent-A-Center

$11.70

0.09 (0.78%)

17:53
01/19/18
01/19
17:53
01/19/18
17:53
Hot Stocks
Vintage Capital in standstill pact with Rent-A-Center »

On January 17, Vintage…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AR

Antero Resources

$18.74

-0.59 (-3.05%)

17:44
01/19/18
01/19
17:44
01/19/18
17:44
Recommendations
Antero Resources analyst commentary at MUFG »

Antero Resources price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$37.21

0.06 (0.16%)

, TWX

Time Warner

$93.36

0.39 (0.42%)

17:44
01/19/18
01/19
17:44
01/19/18
17:44
Periodicals
AT&T requesting docs from companies in Time Warner deal hearing, Reuters says »

AT&T (T) is…

T

AT&T

$37.21

0.06 (0.16%)

TWX

Time Warner

$93.36

0.39 (0.42%)

VZ

Verizon

$51.91

0.36 (0.70%)

CMCSA

Comcast

$42.50

0.65 (1.55%)

CMCSK

Comcast

DISH

Dish

$45.26

0.1 (0.22%)

CHTR

Charter

$366.05

0.8 (0.22%)

DIS

Disney

$110.59

0.17 (0.15%)

VIA

Viacom

$39.20

-0.5 (-1.26%)

VIAB

Viacom

$33.36

-0.59 (-1.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

  • 24

    Jan

  • 31

    Jan

  • 02

    Feb

  • 06

    Feb

  • 08

    Feb

  • 08

    Feb

GRPN

Groupon

$5.57

0.46 (9.00%)

17:44
01/19/18
01/19
17:44
01/19/18
17:44
Hot Stocks
Groupon announces Chief Product Officer Jay Sullivan resigns »

On January 17, Jay…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CELG

Celgene

$102.65

0.93 (0.91%)

17:41
01/19/18
01/19
17:41
01/19/18
17:41
Hot Stocks
Celgene's Abraxane exceeds primary endpoint target in pancreatic cancer trial »

Celgene announced primary…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 25

    Jan

  • 16

    Feb

  • 25

    Mar

VALU

Value Line

$19.60

0.3 (1.55%)

17:40
01/19/18
01/19
17:40
01/19/18
17:40
Hot Stocks
Value Line reaffirms $3M stock repurchase program »

The Board of Directors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VALU

Value Line

$19.60

0.3 (1.55%)

17:39
01/19/18
01/19
17:39
01/19/18
17:39
Hot Stocks
Value Line declares special dividend of 20c per share »

Payable on March 9 to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZEAL

Zealand Pharma

$15.05

-0.78 (-4.93%)

17:34
01/19/18
01/19
17:34
01/19/18
17:34
Hot Stocks
Zealand Pharma: FDA approves IND for Phase 3 trials of dasiglucagon in CHI »

The U.S. FDA has approved…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GNMSF

Genmab

$190.75

2.75 (1.46%)

, JNJ

Johnson & Johnson

$147.36

0.44 (0.30%)

17:29
01/19/18
01/19
17:29
01/19/18
17:29
Hot Stocks
Genmab says FDA grants priority review for daratumumab »

Genmab (GNMSF) announced…

GNMSF

Genmab

$190.75

2.75 (1.46%)

JNJ

Johnson & Johnson

$147.36

0.44 (0.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 23

    Jan

  • 16

    Feb

  • 08

    Mar

HII

Huntington Ingalls

$242.12

5.24 (2.21%)

17:21
01/19/18
01/19
17:21
01/19/18
17:21
Hot Stocks
Huntington Ingalls awarded $125.2M government contract modification »

Huntington Ingalls Inc. -…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Feb

  • 21

    Feb

BAESY

BAE Systems

$33.30

0.18 (0.54%)

, GD

General Dynamics

$209.10

1.3 (0.63%)

17:20
01/19/18
01/19
17:20
01/19/18
17:20
Hot Stocks
BAE Systems, General Dynamics awarded $237.6M government contract modification »

BAE Systems (BAESY) San…

BAESY

BAE Systems

$33.30

0.18 (0.54%)

GD

General Dynamics

$209.10

1.3 (0.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

SYRS

Syros Pharmaceuticals

$10.80

0.27 (2.56%)

17:17
01/19/18
01/19
17:17
01/19/18
17:17
Syndicate
Breaking Syndicate news story on Syros Pharmaceuticals »

Syros Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WTFC

Wintrust Financial

$87.81

0.96 (1.11%)

17:13
01/19/18
01/19
17:13
01/19/18
17:13
Hot Stocks
Wintrust Financial raises its minimum wage to $15 per hour »

Wintrust Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

TWTR

Twitter

$23.66

-0.38 (-1.58%)

17:07
01/19/18
01/19
17:07
01/19/18
17:07
Hot Stocks
Twitter says has identified more IRA and automated Russia-based accounts »

In a statement on its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 07

    Feb

  • 08

    Feb

  • 28

    Feb

ITEK

Inotek Pharmaceuticals

17:04
01/19/18
01/19
17:04
01/19/18
17:04
Hot Stocks
Boxer Capital reports 5.3% passive stake in Rocket Pharmaceuticals »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OIS

Oil States

$32.80

0.35 (1.08%)

17:03
01/19/18
01/19
17:03
01/19/18
17:03
Syndicate
Breaking Syndicate news story on Oil States »

Oil States files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AVGO

Broadcom

$266.39

-3.41 (-1.26%)

, QCOM

Qualcomm

$68.04

-0.01 (-0.01%)

16:43
01/19/18
01/19
16:43
01/19/18
16:43
Hot Stocks
Broadcom receives second request from FTC for proposed Qualcomm deal »

Broadcom (AVGO) announced…

AVGO

Broadcom

$266.39

-3.41 (-1.26%)

QCOM

Qualcomm

$68.04

-0.01 (-0.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

TRNC

tronc

$19.53

0.3 (1.56%)

16:37
01/19/18
01/19
16:37
01/19/18
16:37
Periodicals
LA Times' CEO Ross Levinsohn to take leave of absence amid probe, WSJ says »

Ross Levinsohn, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AP

Ampco-Pittsburgh

$14.20

0.15 (1.07%)

16:35
01/19/18
01/19
16:35
01/19/18
16:35
Syndicate
Breaking Syndicate news story on Ampco-Pittsburgh »

Ampco-Pittsburgh files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Mar

CG

Carlyle Group

$24.35

-0.05 (-0.20%)

, UBSH

Union Bankshares

$38.79

0.54 (1.41%)

16:33
01/19/18
01/19
16:33
01/19/18
16:33
Hot Stocks
Carlyle Group reports 6% passive stake in Union Bankshares »

In a regulatory filing,…

CG

Carlyle Group

$24.35

-0.05 (-0.20%)

UBSH

Union Bankshares

$38.79

0.54 (1.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

ANDX

Andeavor Logistics

$52.52

0.12 (0.23%)

16:31
01/19/18
01/19
16:31
01/19/18
16:31
Hot Stocks
Andeavor Logistics raises quarterly cash distribution to $1.00 per unit »

The fourth quarter…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.